Facebook Twitter RSS Feed

You are here

Structural Heart

 - medical scale

One more reason to tell patients to watch the waistline this holiday season: Research indicates that higher waist-to-hip ratio may result in increased risk for sudden cardiac death.

 - operation, operating room, surgery, intervention

Transcatheter aortic valve replacement (TAVR) likely stepped closer to use in intermediate-risk patients after a multicenter study found patients who underwent transfemoral TAVR with a next-generation valve had a 30-day mortality rate of 2.1 percent.

 - 3D Heart

Cardiac surgeons are learning the utility of 3D printed modeling. As shown Nov. 19 at the American Heart Association scientific session in Chicago, it allows physicians to hold and inspect a rendition of a patient’s heart prior to surgery to get a better understanding of internal anatomy with congenital defects.

 - pills

For patients with Marfan’s syndrome, losartan may not be any better at reducing rates of aortic-root enlargement than beta-blockers. The results challenge prior studies that suggested losartan may have an advantage over beta-blocker therapy.

 - Baby

Critical screening for newborns in New Jersey bears fruit: 13 more babies were identified with critical congenital heart defects than had been previously identified through prenatal screening or physical exam. Secondarily, babies with other kinds of congenital heart defects and serious medical conditions were identified solely through the mandatory pulse oximetry program.


More Stories

Aortic valve replacement study reconsiders guidelines, younger patients

Mechanical and bioprosthetic aortic valve replacements were found to be equally safe and effective for patients aged 50 to 59 years, according to a study published Oct. 1 in JAMA. No difference was seen in stroke or long-term survival rates between the two replacement options.

Repositionable Lotus valve safe, effective at 30 days

A repositionable and retrievable valve proved safe and effective at 30 days in high-risk patients who underwent transcatheter aortic valve replacement. Results from the REPRISE II study were published in the Sept. 30 issue of the Journal of the American College of Cardiology.

St. Jude puts Portico on hold

St. Jude Medical has hit the pause button on its Portico resheathable heart valve used in transcatheter aortic valve replacement (TAVR) procedures after reports of reduced leaflet mobility.

Growing up on statins: Checking up on kids 10 years out

Children with familial hypercholesterolemia who were given statins as treatment slowed the progression of their mean carotid intima media thickness after 10 years of treatment to nearly normal rates, according to research published Sept. 10 in JAMA.

Money & MitraClip

It appears that the Centers for Medicare & Medicaid Services (CMS) may compromise on reimbursement for MitraClip implantations. If so, you probably have your colleagues and societies to thank for it.

Meta-analysis finds 2.5-fold higher pacemaker risk with CoreValve

A meta-analysis of predictors of permanent pacemaker implantation after transcatheter aortic valve replacement (TAVR) reinforced findings that patients treated with the CoreValve device were at increased risk compared with patients receiving the Sapien device. The predictors may help physicians avoid atrioventricular block-related complications, regardless of device type.

Device size, failure mode affect outcomes after valve-in-valve procedure

Patients with baseline stenosis or small surgical valves who undergo transcatheter aortic valve-in-valve implantation for failed bioprosthetic devices have lower survival rates than the overall patient population, according to a study published in the July 9 issue of JAMA.

Women bore brunt of initial NCD for TAVR

Limiting access to transcatheter aortic valve replacement (TAVR) therapy to inoperable patients suitable for only a transfemoral approach reduced the number of patients who received care, particularly women, in a study that evaluated the effect of the national coverage determination (NCD). 

Surgeons warn against use of Mitroflow valve in young patients

Children’s hospital physicians cautioned surgeons against implanting the Mitroflow bioprosthetic aortic valve in young patients who undergo aortic valve replacement and recommended vigilant surveillance of those who already have the device.

Congenital heart disease longevity increasing in Quebec

People with congenital heart disease are living longer and both birth and longevity rates in Quebec and the rest of Canada are comparable to statistics from other industrialized nations. Over time, this is leading to growth of an aging congenital heart disease population, particularly for those with severe disease with comorbid conditions, according to a study published online June 18 in Circulation.

Antidepressants not likely to increase risk of cardiac birth defects

The risk of children developing heart defects due to maternal antidepressant use in the first trimester may be lower than originally thought, according to a study published June 18 in the New England Journal of Medicine. These findings challenge the FDA’s decision to classify selective serotonin-reuptake inhibitors as Category D medications (evidence of human fetal risk, but benefits may warrant use) in pregnancy.

FDA approves next-gen Sapien valve

The FDA has given the green light to Edwards Lifesciences to market its next-generation transcatheter aortic valve replacement (TAVR) device, the Sapien XT, for treatment in inoperable and high-risk patients with severe aortic stenosis.

2D echo may lead to inaccurate sizing in half of TAVR patients

Almost half the patients implanted with a transcatheter aortic valve replacement (TAVR) device received the wrong valve size in a study that compared oversizing using transesophageal echocardiography (TEE) with multislice CT. As a result, the patients received a transcatheter heart valve that was too small.

FDA OKs CoreValve for high-risk patients

The FDA approved the CoreValve device for transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis without a review from an expert panel. While the favorable decision was expected, the road to it developed a few potholes.

Tool IDs patients with poor outcomes after TAVR

A model that includes quality of life (QoL) in its assessment predicted with moderate discrimination patients who likely would have poor outcomes after undergoing transcatheter aortic valve replacement (TAVR), according to results published online May 23 in Circulation.

TAVR triumphs

This week, two titans in transcatheter aortic valve replacement (TAVR) settled a feud over patents. One beneficiary of that agreement may be TAVR itself.

TAVR détente: Edwards, Medtronic settle patent dispute

Edwards Lifesciences and Medtronic reached a cross-license settlement over transcatheter aortic valve replacement (TAVR) devices with provisions that should put their patent dispute to rest.

CMS supports coverage for transcatheter mitral devices

The Centers for Medicare & Medicaid Services (CMS) is proposing to cover transcatheter mitral valve repair, but only if certain conditions are met.

AATS: No signs of risk creep with TAVR

Fears that physicians may be treating patients who are suitable candidates for standard care with less invasive transcatheter aortic valve replacement (TAVR) may be allayed, based on results presented April 28 at the American Association of Thoracic Surgery meeting in Toronto.

AATS: Complex cardiac surgeries may require continued training

Cardiac surgeons may benefit from continuous training if they perform complex or rare procedures, according to an abstract presented April 28 at the American Association for Thoracic Surgery meeting in Toronto.